NEW PROSPECTS FOR CANCER TREATMENT – RESULTS OF THE MEDICAL RESEARCH AGENCY COMPETITION FOR NON-COMMERCIAL CLINICAL TRIALS IN ONCOLOGY
We are pleased to announce that the Medical University of Lodz has received a recommendation for funding for two research projects, in the role of Consortium Member, in the competition organized by the Medical Research Agency for non-commercial clinical trials and research experiments in the field of oncology (ABM/2024/2).
Out of 69 submitted applications, 18 have been selected and recommended for funding. The high ranking of our projects on the list is a significant distinction and a testament to their innovative nature.
1st place – project led by Prof. Bernarda Kazanowska, MD, PhD, from the Wroclaw Medical University (main investigator on behalf of the Medical University of Lodz: Prof. Wojciech Młynarski, MD, PhD):
“Liquid biopsy and comprehensive molecular testing of paediatric soft tissue sarcoma in Poland to improve diagnosis, risk stratification and outcome”
ACRONYM: LiBRha – Liquid Biopsy for Rhabdomyosarcoma
Total project value: 26,227,797.11 PLN
- Project leader: Wroclaw Medical University
- Consortium member: Saving Kids With Cancer Foundation (Fundacja Na Ratunek Dzieciom z Chorobą Nowotworową)
15th place – project led by Prof. Zbigniew Adamczewski, MD, PhD:
“Prognostic value assessment of PSMA-T4 examination in the group of patients with triple-negative breast cancer (TNBC) qualified for radical therapy”
Total project value: 14,773,391.98 PLN
- Project leader: National Centre for Nuclear Research
- Consortium member: Medical University of Gdańsk
The total funding allocated to the Medical University of Lodz from the above projects amounts to nearly 13 million PLN.
Congratulations to our research teams!
We thank everyone who contributed to this success and wish the teams the best of luck in carrying out their research.
At the same time, we are pleased to inform you that the project “Prognostic value assessment of PSMA-T4 examination in the group of patients with triple-negative breast cancer (TNBC) qualified for radical therapy” has been recognized and nominated for presentation at the Medical Research Agency’s press conference dedicated to the competition results.
More information about the conference:
